

CO60

327. IMPLANTE DE PRÓTESIS AÓRTICAS TRANSAPICALES: EXCELENTES RESULTADOS EN PACIENTES DE ALTO RIESGO

Chávez T, Unbehaun A, Pasic M, Buz S, Hetzer R
Deutsches Herzzentrum Berlin, Berlin, Alemania

Objetivos: el implante de prótesis aórticas transapicales (TAVI) es una nueva alternativa terapéutica para los pacientes con estenosis aórtica y elevado riesgo quirúrgico. Analizamos nuestra experiencia inicial.

Métodos: desde abril de 2008, 672 pacientes (edad 79 ± 8 años; rango 28-99) han sido tratados mediante implante de TAVI. El EuroSCORE logístico medio fue de $38 \pm 21\%$ y el *score Society of Thoracic Surgeons* (STS) $18 \pm 15\%$; 25 pacientes (6,1%) presentaban *shock* cardiogénico. Se realizaron los siguientes procedimientos concomitantes: *stent* coronario electivo (46), cirugía de revascularización coronaria (4), reparación tricuspídea (3), cierre de comunicación interauricular (CIA) (1), dilatación de válvula pulmonar (1) y sustitución valvular mitral (1).

Resultados: el implante se llevó a cabo con éxito en el 99,5%. La supervivencia a los 30 días, 1, 2 y 3 años fue del $95,2 \pm 1,1\%$, $83,0 \pm 2,1\%$, $68,3 \pm 3,5\%$, y $63,7 \pm 4,5\%$, respectivamente. En el análisis multivariante se observaron como factores predictores de supervivencia el sexo femenino, ausencia de insuficiencia renal previa, arteriopatía periférica y *shock* cardiogénico.

Conclusiones: el implante de TAVI es factible en pacientes con riesgo prohibitivo para cirugía convencional. Dado que nuestros resultados son excelentes, incluso a medio plazo, consideramos que esta técnica cambiará el futuro de la cirugía cardíaca, abriendo un nuevo camino hacia la cirugía híbrida.

CO61

292. EXTRACORPOREAL MEMBRANE OXYGENATION FOR REFRACTORY CARDIOGENIC SHOCK: A BRIDGE TO DECISION?

Colli A, Tarzia V, Bottio T, Bianco R, Cacciavillani¹ L, Marzari¹ A, Gerosa G
University of Padua, Italy

Objectives: cardiogenic shock refractory to conventional therapy has very high mortality and limited therapeutical options. Aim of the study was to evaluate the impact of the use of ECMO as a life-saving measure when optimal conventional treatment has been reached and mechanical circulatory support is the only option for survival.

Material and methods: between January 2009 and May 2011, 32 patients in cardiogenic shock refractory to optimal conventional therapy (inotropes and intra-aortic-balloon-pump) were treated with the extracorporeal life support implantation. Venous-arterial extracorporeal membrane oxygenation has been implanted either at bedside under local anesthesia or in operating room.

Results: the mean age of the population (24 male and 8 female) was 49 ± 16 years, all patients presented with cardiogenic shock refractory to medical therapy due to various etiology. Venous-arterial extracorporeal membrane oxygenation was

implanted at bedside under local anesthesia in 20 awake patients (63%) and in the operating room in the remaining 12 (37%). Average duration of ECMO support was 12.3 ± 10.2 days (range 1-46). Twenty-six patients (81%) were weaned from venous-arterial extracorporeal membrane oxygenation or bridged to either a ventricular assist device or heart transplantation. ECMO was used as bridge to transplantation in 7 patients (22%), bridge to recovery in 10 patients (31%) and bridge to bridge in 9 patients (28%). Six patients (18.7%) died during ECMO support, whereas 30-day overall survival after ECMO removal was 80.7% (21/26 pts). Sixteen patients (50%) were discharged from the hospital, with a 100% survival at six-months follow-up.

Conclusions: in our experience the use of ECMO as a "bridge to decision" significantly improved the outcome of cardiogenic shock patients, greatly reducing the expected mortality.



BIOMED



unidix

Especialistas en cirugía cardiovascular

desde 1977 al cuidado de tu salud



91 803 28 02



info@biomed.es